IL1A and systemic lupus erythematosus: Hydroxychloroquine has been suggested to reduce the risk of MAS in SLE patients (104), and it is speculated that hydroxychloroquine may reduce the production of IL-1, IL-6, and TNF-α, and inhibit TLRs, thereby reducing the likelihood of developing SLE-MAS.